Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC

被引：0
|
作者：
Law, H. [1 ]
King, J. C. [1 ]
Lin, H. M. [2 ]
Curran, E. [2 ]
Wiens, J. [1 ]
Cruz, L. [3 ]
Blender, J. [4 ]
Venanzi, E. S. [4 ]
Schenk, E. [5 ]
Lin, J. J. [6 ]
机构：
[1] GO2 Lung Canc, Washington, DC USA
[2] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] ALK Posit Inc, Atlanta, GA USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] Mass Gen Canc Ctr, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
care-planning; self-management; 4R;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA05.04
引用
收藏
页码：S113 / S114
页数：2
相关论文
共 50 条
  • [41] Characteristics and treatment of NSCLC patients with ALK translocation, a single centre experience
    Postmus, P. E.
    Yip, K.
    Gosney, J.
    Piskilidis, P.
    LUNG CANCER, 2017, 103 : S30 - S30
  • [42] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Dikopf, Alana
    Wood, Kevin
    Salgia, Ravi
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
  • [43] AN ESTIMATE OF NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH ALK TRANSLOCATION (ALK plus ) IN ITALY ELIGIBLE FOR TREATMENT WITH TYROSINE KINASE INHIBITORS (TKI)
    Demma, F.
    Viti, R.
    VALUE IN HEALTH, 2020, 23 : S456 - S456
  • [44] The Efficacy and Safety of Ceritinib in the Treatment of ALK plus NSCLC: A Systematic Review and Meta-Analysis
    Luo, P.
    Fan, J.
    Xia, Z.
    Zhang, X.
    Chen, Y.
    Qian, R.
    Liu, S.
    You, D.
    Zhang, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [45] The efficacy and safety of alectinib in the treatment of ALK plus NSCLC: a systematic review and meta-analysis
    Fan, Junsheng
    Xia, Zengfei
    Zhang, Xiaoli
    Chen, Yuqing
    Qian, Ruolan
    Liu, Sihan
    You, Danming
    Zhang, Jian
    Luo, Peng
    ONCOTARGETS AND THERAPY, 2018, 11 : 1105 - 1115
  • [46] Treatment and prognosis of ALK plus NSCLC in the routine clinical setting: a single-center experience
    Christopoulos, P.
    Elsayed, M.
    Ristau, J.
    Bozorgmehr, F.
    Heussel, C. P.
    Herth, F.
    Dienemann, H.
    Muley, T.
    Meister, M.
    Bischoff, H.
    Warth, A.
    Endris, V.
    Rieken, S.
    Stenzinger, A.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 172 - +
  • [47] Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
    Qiao, Meng
    Zhao, Chao
    Liu, Qian
    Wang, Yan
    Shi, Jingyun
    Ng, Terry L.
    Zhou, Fei
    Li, Xuefei
    Jiang, Tao
    Yang, Shuo
    Gao, Guanghui
    Xiong, Anwen
    Li, Jiayu
    Li, Wei
    Wu, Fengying
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1452 - +
  • [48] Real-world evidence on treatment patterns and survival among ALK plus NSCLC patients in Canada who discontinue crizotinib treatment.
    Kayaniyil, Sheena
    Hurry, Manjusha
    Wilson, John
    Wheatley-Price, Paul
    Melosky, Barbara L.
    Rothenstein, Jeffrey
    Cohen, Victor
    Koch, Caroline
    Zhang, Jie
    Osenenko, Katherine
    Liu, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] A Prospective Multicenter Study for ALK IHC plus Metastasized NSCLC
    Thunnissen, Erik
    Skov, Bg
    Sorensen, Jens
    Mellemgaard, Anders
    Groen, H. J. M.
    Schuuring, Ed
    Timens, Wim
    Heuvel, Michel V. D.
    De Jong, J.
    Monkhorst, Kim
    De Langen, Joop
    Van der Drift, Miep
    Looijen-Salamon, Monika
    Dingemans, Anne-Marie
    Speel, Ernst-Jan M.
    Samii, Suzy
    Duplaquet, F.
    Weynand, Birgit
    Durando, X.
    Penault-Llorca, Frederique
    Pauwels, Patrick
    Kerr, Keith
    Nicolson, Marianne
    Finn, Stephen P.
    Schildgen, O.
    Bubendorf, Lukas
    Rohtschild, S.
    Hiemstra, Annemieke
    Witte, Birgit
    Smit, Egbert
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S649 - S649
  • [50] Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK plus NSCLC
    Schmid, S.
    Chotai, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1088 - S1088
12345